Newsletter | Sensex may hit 1,00,000 by the year-end: Mark Mobius; PB Fintech's healthcare plans & more

From Mark Mobius expecting Sensex to hit 1,00,000 by the end of the year to PB Fintech's plans of foraying into healthcare — Here are the top 11 news stories across business, global events, tech, and more

featured-image

From Mark Mobius expecting Sensex to hit 1,00,000 by the end of the year to PB Fintech's plans of foraying into healthcare — Here are the top 11 news stories across business, global events, tech, and more NSE #LatestNews⚡️ Sensex may hit 1,00,000 by the end of the year, be ready to buy on corrections, says Mark Mobius Veteran Emerging Markets investor Mark Mobius believes that the Sensex can hit levels of 1,00,000 by the end of the year. That implies a potential upside of 18% from the current levels during the last three months of the year. The BSE Sensex is up 18% so far in 2024 and has delivered positive returns annually every single year since 2015, when it had declined 5%.

The index had declined only once on an annual basis since 2012, with average annual returns being 17%. Read here PB Fintech to invest $100 million for a 20-30% stake in new healthcare company, CEO says Yashish Dahiya, Chairman & Group CEO of PB Fintech, parent company of Policybazaar and Paisabazaar, told CNBC-TV18 in an interaction that the company's move into the healthcare space is subject to board approval. Dahiya said that PB Fintech will be a minority investor in the company through which the healthcare foray will happen.



At an event on Friday, PB Fintech's Co-Founder & Executive Vice Chairman Alok Bansal had mentioned that there will be no reconsideration of the company's foray into the healthcare space and that it is a necessity of the middle class. Read here Max Estates' Gurugram project witnesses pre-sales booking value of ₹4,100 crore within 30 days of launch Max Estates on Monday, September 30, said its first residential development in project in Gurugram - Estate 360 - witnessed pre-sales booking value of ₹4,100 crore, within 30 days of its launch. This surpasses the company's guidance of ₹4,000 crore for FY25.

Estate 360 was launched on August 27, 2024 after receiving its RERA registration on August 16, 2024. The company said it has already received a collection of ₹400 crore. With the successful launch of Estate 360, the company has revised its guidance for the total gross development value potential of the project from ₹4,000 crore to ₹4,800 crore in FY25.

Read here Varun Beverages shares gain after HSBC sees PepsiCo partner hitting ₹780 levels Shares of Varun Beverages Ltd. (VBL), one of the largest bottling partners of food and beverage giant PepsiCo Ltd., opened with gains of as much as 2% on Monday.

Global brokerage firm HSBC has initiated coverage on the stock with a 'Buy' recommendation and a price target of ₹780 per share. HSBC's price target implied a potential upside of nearly 28% from Friday's closing levels. According to the foreign brokerage, Varun Beverages controls 90% of PepsiCo's India bottling volume in a market with low soft drink penetration, compared to a fragmented Coca-Cola system.

Read here #techtalks???? BYD recalling 97,000 top-selling EVs on steering component fault, regulator says BYD has informed the Chinese regulator it is recalling nearly 97,000 electric vehicles (EVs) for a manufacturing fault involving a steering control unit that could lead to fire risks, the market regulator said on Sunday. The Chinese automaker is recalling Dolphin and Yuan Plus EVs manufactured in China between November 2022 and December 2023, according to a statement from the State Administration for Market Regulation (SAMR). The company would ask its dealers to install a physical fix in the recalled cars, the SAMR statement added.

It did not elaborate if any of the affected EVs were exported. Dolphin and Yuan Plus were BYD's two top-selling models in 2023, which in total accounted for 26% of its 3 million cars sold in the year, according to data from the China Association of Automobile Manufacturers. Read here Samsung Galaxy Z Flip6 Review: The perfect Flip is finally here If you are looking for a smartphone that will turn heads, the Samsung Galaxy Z Flip6 is the perfect choice.

It's not just a phone—it's a style statement and a conversation starter. Several people approached me over the last month, inquiring about this intriguing flip phone of 2024. One of the most common questions I got was, “Is it worth the premium price tag?” Here is my definitive answer.

The Samsung Galaxy Z Flip6 maintains the familiar design language of its predecessor, the Galaxy Z Flip5, but with sleeker, flatter edges weighing only 187 grams. The Flex Hinge also closes completely flat end-to-end, leaving no room for dust to get inside the device. It is quite sturdy and halts at any angle you want it to.

Read here #DailyData???? Foreign Tourists in India #PersonalFinance???? ICICI Prudential MF launches Nifty200 Value 30 ETF and Index Fund ICICI Prudential Mutual Fund has introduced two new offerings—the ICICI Prudential Nifty200 Value 30 ETF and the ICICI Prudential Nifty200 Value 30 Index Fund. Both are designed to offer cost-efficient access to value stocks within the Nifty 200 universe. The New Fund Offer (NFO) for both funds opens on September 30, 2024, and will close on October 14, 2024.

Investors can apply with a minimum of ₹100 during the NFO period. These funds fall under the "smart beta" category, providing a value-driven approach for investors seeking long-term growth at a low cost. Read here Income tax audit deadline extended to October 7: Who must file and how to submit online The Central Board of Direct Taxes (CBDT) has extended the deadline for filing tax audit reports for the assessment year (AY) 2024-25.

The previous deadline of September 30, 2024, has now been pushed to October 7, 2024.This extension applies to assessees covered under section 139 of the Income Tax Act, 1961. The decision was made after considering the difficulties faced by taxpayers in electronically filing tax audit reports.

Many taxpayers reported issues with the e-filing portal, which experienced sluggishness, making it difficult to upload reports on time. Read here #ExpertEdge???? Building an AI-ready Workforce: Strategies for modern organisations Organisations ranging from businesses to governments worldwide are racing to keep up with AI as it rapidly becomes an essential technology. According to the recent Dell Technologies Innovation Catalyst Research, there is staunch optimism in India, with around 95% of Indian respondents believing Generative AI (Gen AI) and AI will significantly transform industries in the future.

Entities are now strategising acceleration and coordinating their adoption of these revolutionary technologies. They are looking at how AI can be utilised for growth, increased productivity, improved IT security posture, and an overall acceleration in innovation. As a result, some are even considering new modes of operation today.

Read here Substandard medicines — Why the regulator should expedite action and enforce model punishment The Central Drugs Standard Control Organisation(CDSCO) has in its August 2024 drug alert notification mentioned more than 50 drug formulations manufactured and sold in India as ‘Not of Standard Quality (NSQ)’, raising serious health concerns on their use. These drug formulations, sold in the market as generics or brands, and manufactured by leading pharmaceutical companies, include some of the most sold ones. They include the commonly used antacid pantoprazole (brands: Pan-D, Pantocid, Pantomed), fever medication paracetamol (Paracetamole IP), vitamin tablets and capsules (Vitamin D, C and calcium supplement branded as Shelcal, Softgels ), sildenafil injection (brand: Pulmosil) anti-allergy drug fexofenadine, antibiotics like amoxicillin and potassium clavulanate (brands: Clavem 625, Moxclav 625) anti-diabetic drug metformin hydrochloride (brand: Glycimet SR), respirtory drug montelukast sodium (brand: Montair LC Kid), among others.

Read here #Podcast????️ How much will it really cost to reverse climate change? In this eye-opening episode, we dive deep into the world of climate financing..